Review and expert evaluation of the materials of the European meeting on hypersensitivity to drugs (DHM 2022)

ABSTRACT

The review article discusses the current data on the mechanisms of hypersensitivity drugs reactions (HDRs). The relevance of the problem is associated with a significant prevalence of adverse drug reactions, in the structure of which immune allergic reactions occupy a significant proportion. Adverse drug reactions, according to the literature, occur in 10-20% of hospitalized patients and about 25% of outpatients. A serious problem of HDRs is their overdiagnosis, which affects the results of individual treatment and can have serious consequences in case of misdiagnosis, because it causes appropriate restrictions in the use of necessary drugs. Purpose - to analyze current views and recommendations on the problem of drug allergy;to highlight the issues of the 2022 meeting, which highlighted the problems of drug hypersensitivity. In particular, to show the relationship between viral infections and severe skin reactions, such as skin lesion syndrome with eosinophilia and systemic disorders. The article reviews and proposes algorithms that can be used to prevent the development of complications caused by HDRs. The materials of the article are based on the results of the European Meeting organized by the European Association of Allergists and Immunologists in 2022 in Verona, Italy. In the conclusions it is noted that despite the interest of the health care system and the large number of studies and publications on the problem of drug allergy, today there is an urgent need for accurate diagnostic approaches that will ensure the correct identification of the suspected drug by a combination of necessary tests and determine the cause for the possibility of prescribing appropriate treatment. The new mechanisms, phenotypes and endotypes of HDRs to drug responses discussed in the review are the future keys to preventing further exposure to harmful drugs. Preliminary pharmacogenomic screening (identification of specific human leukocyte antigen genotypes associated with severe skin adverse reactions) for patients of certain groups before prescribing high-risk drugs may become the future for Ukraine. © 2022 Group of Companies Med Expert, LLC. All rights reserved.